Legend Biotech Corporation (NASDAQ:LEGN) traded at $28.1 at last check on Friday, Oct 16, making a downturn move of -5.8% on its previous day’s price.

Looking at the stock we see that its previous close was $29.83 and the beta (5Y monthly) reads 0 with the day’s price range being $28.02 – 29.74. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, LEGN has a high of $43.24 and a low of $24.64. The company’s stock has gained about -16.69% over that past 30 days.

Based on estimates by 3 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Legend Biotech Corporation (LEGN) stock as a Hold, while 3 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.

Looking further, we note that the PEG ratio for the LEGN stock currently stands at 0, and the current price level is -6.54% off its SMA20 and -10.61% from its 50-day simple moving average. The RSI (14) is pointing at 38.34 while the volatility over the past week is 4.57% and jumps to 4.59% over the past one month. The beta value is 0, while the average true range (ATR) is currently pointing at 1.48. The average price target for the stock over the next 12 months is $50.67, with the estimates having a low of $47 and a high of $55. These price ends are 67.26% and +95.73% off the current price level respectively, although investors could be excited at the prospect of a +77.94% if the LEGN share price touches on the median price of $50.

Let’s briefly compare Legend (LEGN) stock to its peers. We find that today’s price change of -5.8% and 0% over the past 12 months for LEGN competes that of Amgen Inc (AMGN), which has seen its stock price rise 0.3% in the latest trading session and is +15.8% over the last one year. Another of its peers Bristol-Myers Squibb Company (BMY) has climbed 1.36% today, and is +16.83% up over the past year, while Gilead Sciences Inc (GILD) is also down -5.8% yet its price remains in the red at 0% over the same period. Amgen has a P/E ratio of 19.26 compared to Legend’s 0 and Bristol-Myers 0. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.01% and 0.39%, respectively, in early deals.

Coming back to Legend Biotech Corporation (NASDAQ:LEGN), we note that the average 3-month trading volume was 202.8 Million, while that of the preceding 10-day period stands at 156.7 Million. Current shares outstanding are 129.24 Million.